Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma

被引:27
作者
Mendler, J. H. [1 ]
Kelly, J. [1 ]
Voci, S. [1 ]
Marquis, D. [1 ]
Rich, L. [1 ]
Rossi, R. M. [1 ]
Bernstein, S. H. [1 ]
Jordan, C. T. [1 ]
Liesveld, J. [1 ]
Fisher, R. I. [1 ]
Friedberg, J. W. [1 ]
机构
[1] Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Dept Internal Med, Rochester, NY 14642 USA
关键词
bortezomib; gemcitabine; hepatotoxicity; Hodgkin's lymphoma; proteasome; relapsed;
D O I
10.1093/annonc/mdn365
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Given the significant activity and tolerability of gemcitabine in patients with relapsed Hodgkin's lymphoma (HL), the critical role that nuclear factor kappa B (NF-kappa B) appears to play in the pathogenesis of this tumor, the ability of bortezomib to inhibit NF-kappa B activity, and laboratory studies suggesting synergistic antitumor effects of gemcitabine and bortezomib, we hypothesized that this combination would be efficacious in patients with relapsed or refractory HL. Patients and methods: A total of 18 patients participated. Patients received 3-week cycles of bortezomib 1 mg/m(2) on days 1, 4, 8, and 11 plus gemcitabine 800 mg/m(2) on days 1 and 8. Results: The overall response rate for all patients was 22% (95% confidence interval 3% to 42%). Three patients developed grade III transaminase elevation: one was removed from the study and two had doses of gemcitabine held. Almost all patients exhibited inhibition of proteasome activity with treatment. Conclusions: The combination of gemcitabine and bortezomib is a less active and more toxic regimen in relapsed HL than other currently available treatments. It poses a risk of severe liver toxicity and should be pursued with caution in other types of cancer.
引用
收藏
页码:1759 / 1764
页数:6
相关论文
共 30 条
[1]   PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study [J].
Alberts, SR ;
Foster, NR ;
Morton, RF ;
Kugler, J ;
Schaefer, P ;
Wiesenfeld, M ;
Fitch, TR ;
Steen, P ;
Kim, GP ;
Gill, S .
ANNALS OF ONCOLOGY, 2005, 16 (10) :1654-1661
[2]   Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804 [J].
Bartlett, N. L. ;
Niedzwiecki, D. ;
Johnson, J. L. ;
Friedberg, J. W. ;
Johnson, K. B. ;
van Besien, K. ;
Zelenetz, A. D. ;
Cheson, B. D. ;
Canellos, G. P. .
ANNALS OF ONCOLOGY, 2007, 18 (06) :1071-1079
[3]   Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206 [J].
Blum, Kristie A. ;
Johnson, Jeffrey L. ;
Niedzwiecki, Donna ;
Canellos, George P. ;
Cheson, Bruce D. ;
Bartlett, Nancy L. .
LEUKEMIA & LYMPHOMA, 2007, 48 (07) :1313-1319
[4]   Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome [J].
Bold, RJ ;
Virudachalam, S ;
McConkey, DJ .
JOURNAL OF SURGICAL RESEARCH, 2001, 100 (01) :11-17
[5]   The fully human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib-induced apoptosis [J].
Böll, B ;
Hansen, H ;
Heuck, F ;
Reiners, K ;
Borchmann, P ;
Rothe, A ;
Engert, A ;
von Strandmann, EP .
BLOOD, 2005, 106 (05) :1839-1842
[6]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[7]   SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone [J].
Chung, V ;
Zhou, B ;
Liu, XY ;
Zhu, L ;
Boo, LM ;
Nguyen, HV ;
Ann, DK ;
Song, J ;
Chen, Y ;
Yen, Y .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (03) :533-540
[8]   Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis [J].
Denlinger, CE ;
Rundall, BK ;
Keller, MD ;
Jones, DR .
ANNALS OF THORACIC SURGERY, 2004, 78 (04) :1207-1214
[9]   Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease [J].
Diehl, V ;
Franklin, J ;
Pfreundschuh, M ;
Lathan, B ;
Paulus, U ;
Hasenclever, D ;
Tesch, H ;
Herrmann, R ;
Dörken, B ;
Müller-Hermelink, H ;
Dühmke, E ;
Loeffler, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2386-2395
[10]   Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial [J].
Duggan, DB ;
Petroni, GR ;
Johnson, JL ;
Glick, JH ;
Fisher, RI ;
Connors, JM ;
Canellos, GP ;
Peterson, BA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :607-614